FDA approves new drug for cystic fibrosis
On July 2, the U.S. Food and Drug Administration (FDA) approved Orkambi (lumacaftor 200 mg/ivacaftor 125 mg) for the treatment…
Several therapies are available to help patients with this progressive disease who develop airway infections.
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.